A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo.
about
Targeting the Checkpoint to Kill Cancer CellsMolecular Aspects of Head and Neck Cancer TherapyA Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapyp38MAPK and MK2 pathways are important for the differentiation-dependent human papillomavirus life cycle.Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signalsCoordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases.Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2.Revisiting p53 for cancer-specific chemo- and radiotherapy: ten years after.Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitorsAntitumor mechanisms when pRb and p53 are genetically inactivated.Roles of p38α mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer.The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.Exploiting the p53 Pathway for Therapy.Molecularly targeted therapies for p53-mutant cancers.Proline isomerisation as a novel regulatory mechanism for p38MAPK activation and functions.Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response.Targeting of non-oncogene addiction.Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.Inhibition of MK2 suppresses IL-1β, IL-6, and TNF-α-dependent colorectal cancer growth.p38 MAPK inhibits nonsense-mediated RNA decay in response to persistent DNA damage in noncycling cells.RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors.MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis.Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer.Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure.Orally bioavailable and blood-brain-barrier penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice.Cellular response to the genotoxic insult: the question of threshold for genotoxic carcinogens
P2860
Q26795781-E82912B4-FE67-4D0F-8CC7-DA1925CF1D57Q28082815-C2A3422B-ED5F-418E-B9A4-E56CF31B4313Q30742035-5B713CC2-5335-4988-86D8-EA3985E0ECFFQ34991379-0096C1A7-97AB-4AB1-8804-F2D04378EB6DQ36738823-BE439C10-6DA0-4121-B722-B70F40BBD1BDQ36783008-7FDEF924-2B8B-4F5A-B08C-A48D61167076Q36930676-36C6EC92-FD0E-456C-B6E7-D7F212DE7774Q37164205-6763FCA4-4CD4-4D36-BA8E-360F2B43C5B6Q38187890-BB129185-6111-45D7-B7B7-FB3747B49EB6Q38261022-E7E5A75E-2A8B-47B2-BEAE-028F8B37CF17Q38285170-5682CC14-19CD-4E9F-B411-864522341346Q38366515-D2B59D27-AF65-47BC-9DF2-B56E1B5E8032Q38717784-1CBC3F39-9CE1-4319-835B-187F737CDA52Q38868212-1B51FB33-7159-4481-A05E-9947E7593286Q38905678-1BF48C99-2D60-44E2-92C1-BC4EE667904DQ39134087-D1ED4595-DF8B-444A-9448-3F49DFF5A4CFQ39393193-E2CF8783-DF70-4F8B-889C-F7C54F16A339Q41636987-9DBF977E-E6E1-4A57-B804-5AE95F7B7E59Q41718028-19ABE19F-6896-4C46-8F88-3778240C315BQ42726616-8171ED75-CA34-4C43-8109-903F5C82F1F7Q47120183-8E6102FB-254B-4950-8E16-CBA7291DB777Q47339278-B0899ED9-748C-4A0D-BF5C-BF475A491734Q48002597-FB07E630-4F11-4751-9818-1B94D97EF24AQ52388109-EC6A8532-63ED-4BCF-9DD5-8CDD753BD7FAQ52718712-A9EC14B1-EB72-44C8-9F60-A6F6E04B4540Q54110522-297FBCCC-5330-4DEB-AA05-176423C1B087Q54115365-7D5C3633-6CB2-475C-9BD6-51F3D927C968Q55457072-E2E79F60-830A-4EE4-9064-C43B08278866Q57073387-B54085F1-1EC5-4BDE-948A-8D58E1D2F2DF
P2860
A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A reversible gene-targeting st ...... e DNA damage response in vivo.
@en
type
label
A reversible gene-targeting st ...... e DNA damage response in vivo.
@en
prefLabel
A reversible gene-targeting st ...... e DNA damage response in vivo.
@en
P2093
P2860
P1433
P1476
A reversible gene-targeting st ...... e DNA damage response in vivo.
@en
P2093
Anthony D Couvillon
Daniela M Ruf
H Christian Reinhardt
Jacob S Kim
Michael B Yaffe
Sandra Morandell
Tanya Mitra
Tyler Jacks
P2860
P304
P356
10.1016/J.CELREP.2013.10.025
P577
2013-11-14T00:00:00Z